ECELLFRANCE is the French Research Infrastructure for mesenchymal stem cell (MSC)-based therapies.
Its mission is to develop cellular therapies based on the use of adult mesenchymal stem cells (MSC). These therapies aim to regenerate damaged tissues in many age-related pathologies and chronic inflammatory diseases currently without curative treatment, and are therefore a major goal in medicine.
The research infrastructure brings together key national actors in an integrated governance with the aim of enabling partners and teams requesting our support to become European leaders in their field of competence.
Since its creation in 2012, ECELLFRANCE has been involved in over 20 national and European research & innovation programs in cell-based therapy.
It brings together:
In the field of:
SITES AND PLATFORMS
ECELLFRANCE BY THE NUMBERS
- 7 sites
- 57 research scientists (without counting clinical staff)
- 11 technological platforms :
- 7 gouvernemental research organisations involved
"Each site is associated with specific activities, technological platforms, and clinical expertise"
ECELLFrance clinical expertise in MSC therapy investigations include: osteoarticular conditions, cutaneous conditions, ischemia, cerebrovascular disorders, immunological disorders and alloreactivity.
ECELLFRANCE is open to academics and industrials requesting support for their pre-clinical and/or clinical programs in the field of cell-based therapies. The infrastructure provides services covering the entire MSC-based production and development pipeline including:
|- Project validation||- Production of ATMP||- Immunomonitoring|
|- Preclinical studies||
- Safety and potency tests
- Regulatory support
- Phase I and II clinical trials
Full service offering available here